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values and mortality rates were obtained from published litera-
ture. Costs in each state were obtained from local observational
studies and ofﬁcial, local unit costs or from published literature.
A lifetime horizon was taken. Discount rates varied according
to local guidelines. RESULTS: The base-case incremental cost-
utility was €18213 (£13111)/QALY, €7605 (SEK 70379)/QALY,
€17592/QALY and €7990/QALY in the UK, Sweden, Italy and
Belgium, respectively. Assuming a threshold of €30,000/QALY,
DRV/r remained cost-effective over most parameter ranges tested
in extensive one-way sensitivity analyses. Probabilistic sensitivity
analysis revealed a probability of = 67% of an ICER below this
threshold in all countries. CONCLUSIONS: From the British,
Swedish, Italian and Belgian payer perspective, DRV/r 600/
100 mg bid is predicted to be cost-effective versus LPV/r in the
management of LPV/r-naïve, PI-resistant, HIV-infected adults
with a broad range of prior PI use/failure.
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OBJECTIVES: Ten years ago, Canada switched from whole cell
to acellular pertussis vaccine (AcE) from the whole cell product
(WCE) due to superior efﬁcacy and safety, but at an increased
cost. We performed a pharmacoeconomic analysis from societal
(direct+indirect costs) and Ministry of Health (MoH; direct costs
only) perspectives for Canadian children, comparing costs and
outcomes before and after the switch. METHODS: An epidemio-
logic model was constructed to portray the costs and outcomes
for a cohort of children born 1991–1996 compared with another
cohort born 1999–2004. The years between constituted the tran-
sition period. The model extended until children were age 13
(expected coverage period of pediatric immunization for pertus-
sis). Direct costs included vaccines and disease management
(pediatrician visits, emergency room visits, pediatric ICU and
ward stays, antibiotics). Indirect costs included parental time for
vaccination and hospital visits. Cost values were applied from
standard lists and projected to constant 2005 dollars, with costs
form other years discounted at 5%. Literature estimates were
used for infection rates, mortality rates, and clinical rates
(vaccine success, adverse events). Outcomes examined were per-
tussis cases avoided and pertussis hospitalizations avoided, both
discounted at 5%. Pharmacoeconomic outcomes were the incre-
mental costs per case avoided. Robustness of results was tested
with a variety of one-way and multivariate sensitivity analyses.
RESULTS: The total MoH was $238 million for WCE and $256
million for AcE; total societal costs were $540 million and $510
million, respectively. Cases decreased from 246,063 with WCE
to 106,088 with AcE and hospital admissions from 1038 to 441.
The MoH incremental cost/case avoided was $108 ($0.96/child).
From the societal perspective, there were cost savings. Sensitivity
analyses conﬁrmed that results were robust. CONCLUSIONS:
We found that pertussis vaccination with AcE was cost saving
from the societal perspective and cost-effective from the Ministry
of Health perspective.
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OBJECTIVES: To determine the cost-effectiveness of 7-valent
PCV in a national immunisation programme in Turkey.
METHODS: A model was developed in MS-Excel™ to estimate
the incidence of four diseases: pneumococcal meningitis, pneu-
mococcal septicaemia/bacteraemia, all-cause pneumonia and all-
cause acute otitis media in a cohort of children zero to ten years
of age. The efﬁcacy of the vaccine against these conditions was
assumed to be 97.4%, 97.4%, 7% and 6% respectively. In addi-
tion, corresponding adult disease burden was incorporated into
the model by assuming reductions of 32%, 8% and 18% in the
age groups 20–39 yrs, 40 to 64 yrs and 65 + yrs respectively, due
to indirect (herd) effects. Turkish data used were from reports of
the Ministry of Health, the Turkish Statistics Organisation, data
from 11 major hospitals in Istanbul (serving about 80% of the 12
million city population), the National Burden of Disease Survey
and the Verbal Autopsy Study. When Turkish data were not
available, estimates were developed through expert opinion
and/or extrapolated data. When paediatric costs were not known
they were assumed to be one-tenth of UK costs; when adult costs
were not known they were assumed to be one-ﬁfth of UK costs.
It was estimated that 1972 annual adult deaths occured due to
pneumococcal infection in Turkey. The estimated serotype cov-
erage for invasive pneumococcal diseases was 63% for those
<2 yrs of age and 35% for those 2 to 10 yrs of age. It was
assumed that only 80% of the primary birth cohort would be
vaccinated and the schedule would be 4 doses. RESULTS: The
addition of indirect (herd) effects to the model reduced the cost-
effectiveness by 12.5%. If one-tenth of the recognised cost-
effectiveness threshold (US$60,000 cost per life-year gained) is
taken as the cost-effectiveness threshold for Turkey ie US$6000,
then 7-valent PCV would be cost effective at a cost-per-dose of
US$45. The costs per QALY in Turkey for the treatment of
lung cancer is US$6141 and for hepatitis C treatment US$6638.
CONCLUSIONS: The inclusion of 7-valent PCV in a fully-
funded Turkish national immunisation programme would be
highly cost-effective.
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OBJECTIVES: The purpose of this study is to evaluate cost-
effectiveness and cost-utility of peginterferon alfa-2a (PEGASYS)
plus ribavirin (PEGIFN+RIB) versus no treatment, in HIV/HCV
co-infected patients in Portugal. METHODS: A 9-state Markov
model was developed to simulate the disease progression based
on the APRICOT clinical trial population (40-year old patients
with HIV/HCV co-infection; genotypes 1, 2/3 and 1/2/3) using
the METAVIR scoring system to stage liver disease. The model
included the following health states: no ﬁbrosis; portal ﬁbrosis,
no septa; portal ﬁbrosis, few septa; septal ﬁbrosis, no cirrhosis;
cirrhosis; decompensated cirrhosis; hepatocellular carcinoma;
liver transplant and death. The ﬁbrosis progression rates, transi-
tion probabilities and quality of life estimates were obtained
from reference studies. Efﬁcacy in terms of sustained virologi-
cal response for PEGIFN+RIB therapy was obtained from
APRICOT clinical trial. A lifetime horizon was considered. The
analysis assumes the National Health System perspective. Portu-
guese clinical practice was characterized from a consensus
experts panel, including patients’ diagnosis and follow-up, geno-
type distribution and main resources used. Unit costs were
obtained from ofﬁcial data. Costs and outcomes were discounted
by three percent annually. One-way sensitivity analysis was per-
formed on non-HCV treatment costs, time horizon, genotype
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distribution, discount rate and non performing transplant.
RESULTS: In the combined analysis, considering the expected
genotypic distribution for the Portuguese population, treatment
with PEGIFN+RIB was estimated to increase discounted life
expectancy by 1.61 years (23.30 vs 2169) and quality-adjusted
life expectancy by 1.17 QALYs compared to no treatment. Direct
costs were projected to be €29,410 with PEGIFN+RIB and
€33,788 with no treatment. These results corresponded to ICERs
of -€2.19 and -€3742 per life year gained and per QALY gained,
respectively. CONCLUSIONS: The use of of PEGIFN+RIB
(PEGASYS/COPEGUS) vs no treatment in patients with HIV/
HCV co-infection is a cost-saving (dominant) alternative in the
Portuguese setting for all genotypes.
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OBJECTIVES: To estimate the cost-effectiveness of caspofungin
versus amphotericin B, voriconazole, and anidulafungin in the
treatment of invasive candidiasis in a subgroup of patients who
are infected by ﬂuconazole-resistant Candida species and in
patients who cannot be treated with ﬂuconazole due to other
reasons. METHODS: For this analysis a lifetime Markov model
was used with following health states: success, failure, and death
over two treatment lines. A randomized clinical trial comparing
caspofungin and amphotericin B was used to estimate daily tran-
sition probabilities. The corresponding probabilities for vori-
conazole and anidulafungin were estimated based on indirect
comparisons using amphotericin B as the common comparator.
The analysis was conducted from a societal perspective. Direct
costs inside the health care system were included. Outcomes were
reported as cost per life-year gained. To determine the robustness
of the model and the impact of uncertainty, uni- and multivariate
sensitivity analyses were carried out. RESULTS: In the base case
analysis the 95% conﬁdence intervals of the incremental life
years were estimated at 0.23(-0.29, 0.85), 0.21(-0.31, 0.88),
and 0.11(-0.37, 0.71) compared to amphotericin B, voricona-
zole, and anidulafungin respectively. Corresponding intervals for
incremental costs were €1825(-€3954, €5581), €40(-€5243,
€3354), and -€415(-€4938, €2570). Cost per life year gained
was €7942 and €189 compared to amphotericin B and voricona-
zole. Caspofungin was dominant compared to anidulafungin.
Probabilistic sensitivity analyses showed that at a willingness to
pay threshold of €20,000/QALY, caspofungin has a 62%, 72%,
and 68% probability to be cost-effective relative to respectively
amphotericin B, voriconazole and anidulafungin. Univariate sen-
sitivity analyses showed that results were sensitive to changes in
efﬁcacy parameters and infection-related mortality. CONCLU-
SIONS: The present model suggests that caspofungin is cost-
effective in the treatment of invasive candidiasis in this speciﬁc
subgroup of patients. Potential limitation of the model is that
efﬁcacy and failure estimates are partly based on indirect
comparisons.
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OBJECTIVES: This study evaluated the cost-effectiveness of
peginterferon alfa-2b (1.5 mcg/kg/wk) plus 800–1400 mg/day
ribavirin (PEG2b 1.5/R) in patients with refractory chronic
hepatitis C (HCV) whose previous combination therapy with
pegylated or standard interferon alfa and ribavirin failed.
METHODS: A Markov model was developed based on an
open-label trial (EPIC) in which patients received PEG2b 1.5/R
or no further drug therapy. Patients with genotypes 1/4 (G1/4)
HCV with undetectable HCV RNA at week 12 were treated for
48 weeks; patients with detectable HCV RNA were discontin-
ued at 18 weeks. G2/3 HCV patients were treated for 24
weeks. Data on the natural history of disease, drug and medical
resource costs (2007 euros), and utility values were estimated
from published literature. Using a Spanish perspective, the
model estimated the incremental cost-effectiveness ratio (ICER)
for PEG2b 1.5/R vs. no further treatment based on cost per
quality-adjusted life year (QALY) gained over a patient’s life-
time. A second-order probabilistic Monte Carlo sensitivity
analysis was conducted to assess the effects of parameter uncer-
tainty (efﬁcacy) on the study ﬁndings. RESULTS: In G1 and G4
patients, PEG2b 1.5/R led to higher costs (€19,300 vs. €10,100)
and increased QALYs (10.62 vs. 10.15) compared with no drug
therapy (ICER: €19,600 per QALY gained). In G2/3 patients,
treatment costs were twice as high for the PEG2b 1.5/R
regimen compared with no therapy (€22,200 vs. €10,100); the
incremental gain in QALYs was greater than it was for the G1
and G4 groups (11.99 vs. 10.15) (ICER: €6,600 per QALY
gained). The probabilistic sensitivity analysis suggests a 99%
probability that the ICER for PEG2b 1.5/R among refractory
patients is at or below a €30,000 per QALY gained threshold
for both genotype groups. CONCLUSIONS: PEG2b 1.5/R is in
the range of the widely accepted cost-effectiveness threshold for
medical interventions in Spain.
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OBJECTIVES: To systematically review the evidence for long-
term effectiveness and cost-effectiveness of screening for hepatitis
C virus (HCV) infection. METHODS: We performed a system-
atic literature search (March 2007) on the long-term health and
economic effects of HCV screening. We included health technol-
ogy assessment (HTA) reports, systematic reviews, long-term
clinical trials, full health economic studies and decision-analytic
modelling studies assessing the impact of HCV screening with a
sufﬁciently long time horizon and a patient-relevant long-term
outcome such as life-years gained (LYG) or quality-adjusted life
years (QALY) gained. Economic results were converted to 2005
Euros. RESULTS: Ten studies were included. Target population,
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